Increased numbers but functional defects of CD56+CD3+ cells in lung cancer

International Immunology

Volumn 24, Issue 7, 2012, Pages 409-415

  Al Omar, Suliman Y ^a,d   Marshall, Ernie ^b   Middleton, Derek ^a,c   Christmas, Stephen E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^c ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

CD25; CD56; CD69; IFN ; Lung cancer: killer immunoglobulin like receptors; T cells

Indexed keywords

CD31 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; HLA B ANTIGEN; HLA BW4 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER STAGING; CD25+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD56+ CELL; CELL ACTIVATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; UPREGULATION;

ANTIGENS, CD3; ANTIGENS, CD56; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELLS, CULTURED; HLA-B ANTIGENS; HUMANS; INTERFERON-GAMMA; LUNG NEOPLASMS; LYMPHOCYTE COUNT; NEOPLASM STAGING; RECEPTORS, KIR2DL1; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 84864022729     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxr122     Document Type: Article

References (34)

1. Lanier, L. L., Le, A. M., Civin, C. I., Loken, M. R. and Phillips, J. K. 1986. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 136:4480.
2. Schmidt-Wolf, I. G., Lefterova, P., Mehta, B. A. et al. 1993. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp. Hematol. 21:1673.
3. Lanier, L. L., Kipps, T. J. and Phillips, J. H. 1985. Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen). J. Exp. Med. 162:2089.
4. Stronge, V. S., Salio, M., Jones, E. Y. and Cerundolo, V. 2007. A closer look at CD1d molecules: new horizons in studying NKT cells. Trends Immunol. 28:455.
5. Gütgemann, S., Frank, S., Strehl, J. and Schmidt-Wolf, I. G. 2007. Cytokine-induced killer cells are type II natural killer T cells. Ger. Med. Sci. 5:Doc07.
6. Terabe, M. and Berzofsky, J. A. 2008. The role of NKT cells in tumor immunity. Adv. Cancer Res. 101:277.
7. D'Arena, G., Musto, P., Cascavilla, N. et al. 1998. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features. Haematologica 83:197.
8. Weng, P. J., Ying, H., Hong, L. Z., Zhou, W. H., Hu, Y. R. and Xu, C. H. 2008. An analysis of CD3+CD56+ lymphocytes and their subsets in the peripheral blood of patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 16:654.
9. Watanabe, H., Weerasinghe, A., Miyaji, C. et al. 2003. Expansion of unconventional T cells with natural killer markers in malaria patients. Parasitol. Int. 52:61.
10. Srivastava, R., Aggarwal, R., Bhagat, M. R., Chowdhury, A. and Naik, S. 2008. Alterations in natural killer cells and natural killer T cells during acute viral hepatitis E. J. Viral Hepat. 15:910.
11. Li, W. X., Pan, H. F., Hu, J. L. et al. 2010. Assay of T- and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus. Clin. Rheumatol. 29:315.
12. Eleftheriadis, T., Kartsios, C., Yiannaki, E. et al. 2009. Decreased CD3+CD16+ natural killer-like T-cell percentage and zeta-chain expression accompany chronic inflammation in haemodialysis patients. Nephrology 14:471.
13. Basak, P. Y., Adiloglu, A. K., Koc, I. G., Tas, T. and Akkaya, V. B. 2008. Evaluation of activatory and inhibitory natural killer cell receptors in non-segmental vitiligo: a flow cytometric study. J. Eur. Acad. Dermatol. Venereol. 22:970.
14. Urbanowicz, R. A., Lamb, J. R., Todd, I., Corne, J. M. and Fairclough, L. C. 2010. Enhanced effector function of cytotoxic cells in the induced sputum of COPD patients. Respir. Res. 11:76.
15. Tajiri, K., Shimizu, Y., Tsuneyama, K. and Sugiyama, T. 2009. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 21:673.
16. Lu, P. H. and Negrin, R. S. 1994. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol. 153:1687.
17. Bamias, A., Tsiatas, M. L., Kafantari, E. et al. 2007. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Gynecol. Oncol. 106:75.
18. Gulubova, M., Manolova, I., Kyurkchiev, D., Julianov, A. and Altunkova, I. 2009. Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases. APMIS 117:870.
19. Wang, H., Yang, S., Xu, W. et al. 2008. Tumor-derived soluble MICs impair CD3(+)CD56(+) NKT-like cell cytotoxicity in cancer patients. Immunol. Lett. 120:65.
20. Zhu, B. Q., Ju, S. W. and Shu, Y. Q. 2009. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses. Biomed. Pharmacother. 63:509.
21. Bonanno, G., Iudicone, P., Mariotti, A. et al. 2010. Thymoglobulin, interferon-c and interleukin-2 efficiently expand cytokineinduced killer (CIK) cells in clinical-grade cultures. J. Transl. Med. 8:129.
22. Lanier, L. L. 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9:495.
23. Gati, A., Guerra, N., Gaudin, C. et al. 2003. CD158 receptor controls cytotoxic T-lymphocyte susceptibility to tumor-mediated activation-induced cell death by interfering with Fas signalling. Cancer Res. 63:7475.
24. Dunne, J., Lynch, S., O'Farrelly, C. et al. 2001. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15. J. Immunol. 167:3129.
25. Franceschetti, M., Pievani, A., Borleri, G. et al. 2009. Cytokineinduced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp. Hematol. 37:616.
26. Linn, Y. C. and Hui, K. M. 2003. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk. Lymphoma 44:1457.
27. Wang, Y., Zheng, X., Wei, H., Sun, R. and Tian, Z. 2008. Different roles of IL-15 from IL-2 in differentiation and activation of human CD3+CD56+ NKT-like cells from cord blood in long term culture. Int. Immunopharmacol. 8:927.
28. Gritzapis, A. D., Dimitroulopoulos, D., Paraskevas, E., Baxevanis, C. N. and Papamichail, M. 2002. Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants. Cancer Immunol. Immunother. 51:440.
29. Yuen, M. F. and Norris, S. 2001. Expression of inhibitory receptors in natural killer (CD3(-)CD56(+)) cells and CD3(+)CD56(+) cells in the peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Clin. Immunol. 101:264.
30. Ugolini, S. and Vivier, E. 2000. Regulation of T cell function by NK cell receptors for classical MHC class I molecules. Curr. Opin. Immunol. 12:295.
31. Bojarska-Junak, A., Hus, I., Sieklucka, M. et al. 2010. Natural killerlike T CD3+/CD16+CD56+ cells in chronic lymphocytic leukemia: intracellular cytokine expression and relationship with clinical outcome. Oncol. Rep. 24:803.
32. Kim, H. M., Lim, J., Park, S. K. et al. 2007. Antitumor activity of cytokine-induced killer cells against human lung cancer. Int. Immunopharmacol. 7:1802.
33. Li, H., Zhao, H., Yu, J. et al. 2011. Increased prevalence of regulatory T cells in the lung cancer microenvironment: a role of thymic stromal lymphopoietin. Cancer Immunol. Immunother. 60:1587.
34. Al Omar, S. Y., Marshall, E., Middleton, D. and Christmas, S. E. 2011. Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer. Immunology 133:94.